Great West Life Assurance Co. Can held its stake in shares of NxStage Medical Inc. (NASDAQ:NXTM) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,228 shares of the medical device company’s stock at the end of the second quarter. Great West Life Assurance Co. Can’s holdings in NxStage Medical were worth $123,000 as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in NXTM. Swiss National Bank raised its stake in shares of NxStage Medical by 15.3% in the second quarter. Swiss National Bank now owns 106,800 shares of the medical device company’s stock valued at $2,315,000 after buying an additional 14,200 shares during the period. Columbus Circle Investors purchased a new stake in shares of NxStage Medical during the second quarter valued at $4,567,000. American Century Companies Inc. purchased a new stake in shares of NxStage Medical during the second quarter valued at $1,329,000. Bank of Montreal Can purchased a new stake in shares of NxStage Medical during the second quarter valued at $14,911,000. Finally, Fox Run Management L.L.C. purchased a new stake in shares of NxStage Medical during the second quarter valued at $245,000. 98.26% of the stock is owned by institutional investors.
Shares of NxStage Medical Inc. (NASDAQ:NXTM) traded down 1.45% on Monday, hitting $24.42. The stock had a trading volume of 254,869 shares. The stock’s market capitalization is $1.58 billion. NxStage Medical Inc. has a 52 week low of $13.49 and a 52 week high of $26.07. The firm has a 50-day moving average price of $23.87 and a 200-day moving average price of $19.74.
NxStage Medical (NASDAQ:NXTM) last announced its quarterly earnings results on Thursday, August 4th. The medical device company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.01. The firm had revenue of $92.20 million for the quarter, compared to the consensus estimate of $89.44 million. NxStage Medical had a negative return on equity of 3.79% and a negative net margin of 2.06%. The company’s quarterly revenue was up 14.8% on a year-over-year basis. During the same period in the prior year, the company posted ($0.08) earnings per share. Equities analysts expect that NxStage Medical Inc. will post ($0.12) earnings per share for the current fiscal year.
Several equities research analysts recently weighed in on the company. Northland Securities set a $25.00 price objective on NxStage Medical and gave the stock a “buy” rating in a report on Thursday, September 15th. Zacks Investment Research lowered NxStage Medical from a “buy” rating to a “hold” rating in a report on Wednesday, August 10th. BTIG Research reissued a “buy” rating and issued a $29.00 price objective on shares of NxStage Medical in a report on Sunday, August 7th. Jefferies Group lifted their price objective on NxStage Medical from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Friday, August 5th. Finally, Canaccord Genuity lifted their target price on NxStage Medical from $22.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, August 2nd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $26.43.
In other NxStage Medical news, Director Craig W. Moore sold 3,000 shares of the stock in a transaction dated Wednesday, September 14th. The stock was sold at an average price of $23.31, for a total value of $69,930.00. Following the transaction, the director now owns 90,739 shares of the company’s stock, valued at $2,115,126.09. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 4.70% of the stock is owned by company insiders.
About NxStage Medical
NxStage Medical, Inc is a medical technology company. The Company is engaged in the development, manufacturing and marketing of products and services for patients suffering from chronic or acute kidney failure. The Company operates through three segments: System One, In-Center and Services. It offers its products and services to various markets, such as home, critical care and in-center.
Want to see what other hedge funds are holding NXTM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NxStage Medical Inc. (NASDAQ:NXTM).
Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.